Annual Report 2024 - Gerresheimer AG

In 2024, we strengthened and broadened our foundation for profitable growth through capacity expansions, the acquisition of Bormioli pharma and innovations.

We have ramped-up new production lines in the USA, Czech Republic and Republic of North Macedonia for drug delivery systems such as pens, auto-injectors and syringes. With the acquisition of Bormioli Pharma we have added an attractive, highly complementary product portfolio, welcomed 1,400 skilled employees into our group and laid the foundation for new, integrated high-value solutions.

We have formed new partnerships to leverage connected devices for remote therapeutic monitoring and medication adherence and added new systems and solutions dedicated to large-molecule biologics.

We have underlined the resilience of our business model in adverse market conditions.

Our fiscal year 2024 at a glance

2.9 %

Organic revenue growth

4.1 %

Organic growth
in Adjusted EBITDA

Financial Year 2024 at a glance

Two success stories will have one joint future! 2025, we will focus on the integration of Bormioli Pharma to leverage the opportunities of the combined portfolio and new capabilities in system integration.

Dietmar Siemssen

CEO

Management Outlook 2025

The five strategic fields of action to our success

Growth

Our transformation into a systems and
solutions provider is driving our sustainable profitable growth.

Innovation

Our innovative products, solutions and processes contribute to health and well-being.

Excellence

The foundation and driver of our growth and success is the focus on the highest quality.

Leadership

People at the heart of our success: Our People & Organization strategy is the key to successful transformation.

Sustainability

Thinking and acting sustainably is part of our corporate strategy.

Downloads

- Gerresheimer AG

- Gerresheimer AG

- Gerresheimer AG

- Gerresheimer AG